Relationship between donor source, pre-transplant measurable residual disease, and outcome after allografting for adults with acute myeloid leukemia

Leukemia

Pre-emptive detection and evolution of relapse in acute myeloid leukemia by flow cytometric measurable residual disease surveillance

Leukemia

McCarthy N, Gui G, Dumezy F, Roumier C, Andrew G, Green S, Jenkins M, Adams A, Khan N, Craddock C, Hourigan CS, Plesa A, Freeman S

doi: 10.1038/s41375-024-02300-z

Leukemia

Comparable relapse incidence after unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide versus conventional anti-graft versus host disease prophylaxis in patients with acute myeloid leukemia: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Am J Hematol

Nagler A, Ngoya M, Galimard JE, Labopin M, Blau IW, Kröger N, Gedde-Dahl T, Schroeder T, Burns D, Salmenniemi U, Rambaldi A, Choi G, Peffault de Latour R, Vydra J, Sengeloev H, Eder M, Mielke S, Forcade E, Kulagin A, Ciceri F, Mohty M

doi: 10.1002/ajh.27383

Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

JAMA Oncol

Dillon LW, Gui G, Ravindra N, Andrew G, Mukherjee D, Wong ZC, Huang Y, Gerhold J, Holman M, D'Angelo J, Miller J, Higgins J, Salk JJ, Auletta JJ, El Chaer F, Devine SM, Jimenez-Jimenez AM, De Lima MJG, Litzow MR, Kebriaei P, Saber W, Spellman SR, Zeger SL, Page KM, Hourigan CS

doi: 10.1001/jamaoncol.2024.0985

Leukemia

Different impacts of granulocyte colony-stimulating factor administration on allogeneic hematopoietic cell transplant outcomes for adult acute myeloid leukemia according to graft type

Am J Hematol

Konuma T, Kameda K, Morita K, Kondo T, Kimura F, Nakasone H, Ouchi F, Uchida N, Tanaka M, Nishida T, Fukuda T, Hasegawa Y, Sakata-Yanagimoto M, Onizuka M, Sawa M, Ota S, Asada N, Fujiwara SI, Yoshihara S, Ishimaru F, Yoshimitsu M, Kanda Y, Ohbiki M, Atsuta Y, Yanada M

doi: 10.1002/ajh.27521

Leukemia

Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study

Blood Cancer J

Hirsch P, Lambert J, Bucci M, Deswarte C, Boudry A, Lambert J, Fenwarth L, Micol JB, Terré C, Celli-Lebras K, Thomas X, Dombret H, Duployez N, Preudhomme C, Itzykson R, Delhommeau F

doi: 10.1038/s41408-024-01078-8

Leukemia

Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML

Am J Hematol

Orvain C, Ali N, Othus M, Rodríguez-Arbolí E, Milano F, Le CM, Sandmaier BM, Scott BL, Appelbaum FR, Walter RB

doi: 10.1002/ajh.27259

Leukemia

Peripheral blood stem cell versus bone marrow graft for patients ≥60 years undergoing reduced intensity conditioning haploidentical transplantation for acute myeloid leukemia in complete remission: An analysis of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Am J Hematol

Devillier R, Galimard JE, Blaise D, Raiola AM, Bramanti S, Grillo G, Pastano R, de Latour RP, Busca A, López-Corral L, Rodríguez AB, Schmid C, Forcade E, Vydra J, Solano C, Bug G, Neubauer A, Charbonnier A, Brissot E, Nagler A, Ciceri F, Mohty M

doi: 10.1002/ajh.27343

Leukemia

Measurable Residual Disease and Clinical Outcomes in Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis

JAMA Oncol

Rios-Olais FA, McGary AK, Tsang M, Almader-Douglas D, Leis JF, Buras MR, Hilal T

doi: 10.1001/jamaoncol.2024.2122

Leukemia

Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients

Blood Cancer J

Schmälter AK, Ngoya M, Galimard JE, Bazarbachi A, Finke J, Kröger N, Bornhäuser M, Stelljes M, Stölzel F, Tischer J, Schroeder T, Dreger P, Blau IW, Savani B, Giebel S, Esteve J, Nagler A, Schmid C, Ciceri F, Mohty M

doi: 10.1038/s41408-024-01060-4

Related content

Pre-emptive detection and evolution of relapse in acute myeloid leukemia by flow cytometric measurable residual disease surveillance

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Different impacts of granulocyte colony-stimulating factor administration on allogeneic hematopoietic cell transplant outcomes for adult acute myeloid leukemia according to graft type

Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study

Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML

Measurable Residual Disease and Clinical Outcomes in Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis

Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients